Twist Bioscience Corporation (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by Brenda Bartman on May 23rd, 2026

Shares of Twist Bioscience Corporation (NASDAQ:TWST – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $58.00.

Several analysts have issued reports on the company. Evercore upped their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Leerink Partners set a $80.00 target price on Twist Bioscience in a report on Friday. Barclays upped their target price on Twist Bioscience from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Guggenheim upped their target price on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th.

Read Our Latest Analysis on Twist Bioscience

Twist Bioscience Stock Up 3.0%

Shares of NASDAQ:TWST opened at $60.57 on Friday. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $52.57 and a two-hundred day moving average of $43.26. The stock has a market cap of $3.77 billion, a P/E ratio of -45.54 and a beta of 2.22. Twist Bioscience has a 52-week low of $23.30 and a 52-week high of $66.06.

Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.66) earnings per share. On average, research analysts expect that Twist Bioscience will post -1.86 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, Director Melissa A. Starovasnik sold 1,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the completion of the transaction, the director directly owned 25,722 shares in the company, valued at approximately $1,311,822. This represents a 3.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Chess sold 10,000 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total value of $470,000.00. Following the transaction, the director owned 21,084 shares of the company’s stock, valued at approximately $990,948. This represents a 32.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 46,551 shares of company stock worth $2,566,533. Insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently modified their holdings of the business. Stifel Financial Corp grew its holdings in shares of Twist Bioscience by 3.6% during the 4th quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after purchasing an additional 271 shares during the period. D.A. Davidson & CO. grew its holdings in shares of Twist Bioscience by 1.2% during the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock worth $801,000 after purchasing an additional 305 shares during the period. CWM LLC grew its holdings in shares of Twist Bioscience by 9.4% during the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares during the period. California State Teachers Retirement System grew its holdings in shares of Twist Bioscience by 0.8% during the 2nd quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after purchasing an additional 442 shares during the period. Finally, Smartleaf Asset Management LLC grew its holdings in shares of Twist Bioscience by 70.6% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares during the period.

About Twist Bioscience

(Get Free Report)

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.